1295746709

1295746709 was paid $2.31M by Medicaid between Jan 2018 and Jun 2021, across 13 billing codes. Its largest line is J0135, Injection, adalimumab, 20 mg — 37% of everything it billed.

33Billing provider info1295746709

33aNPI1295746709

33bProvider type—

28Total paid$2.31M

24GClaims6,745

24DCodes billed13

24AFirst – last monthJan 2018 – Jun 2021

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,422	$1.71M
2019	2,994	$420K
2020	1,889	$155K
2021	440	$22K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
J0135	Injection, adalimumab, 20 mg	37%	1,696	1,377	$851K
J1438	Injection, etanercept, 25 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	21%	793	645	$482K
J2357	Injection, omalizumab, 5 mg	19%	835	637	$444K
J3490	Unclassified drugs	17%	1,736	1,536	$388K
J1726	Injection, hydroxyprogesterone caproate, (makena), 10 mg	4.0%	456	338	$92K
J2182	Injection, mepolizumab, 1 mg	<1%	25	24	$18K
J2941	Injection, somatropin, 1 mg	<1%	36	24	$15K
J3590	Unclassified biologics	<1%	710	533	$8K
J1650	Injection, enoxaparin sodium, 10 mg	<1%	54	51	$5K
S5000	Prescription drug, generic	<1%	51	39	$3K
J8521	Capecitabine, oral, 500 mg	<1%	23	15	$1K
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	<1%	296	265	$234.69

1 more codes

Q0512

Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period

<1%

$16.20

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.